I think that also - "curious choice of words" indeed.
I'm inclined to think its about recruiting patients for our clinical trials as quickly and effectively as possible while tapping available govt funding in both the US and Aust. I reckon the strategy is to maximise the power of our cross-functional teams to take advantage of the FDA's new direction in cell therapy development and the endless grants available.
Ann: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete, page-77
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.76K | 2.928M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 4817793 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18563373 | 21 |
View Market Depth
| Last trade - 14.13pm 26/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |